UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 12, 2010
CPEX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
     
1-33895   26-1172076
 
(Commission file number)   (IRS Employer Identification Number)
2 Holland Way, Exeter, New Hampshire 03833
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (603) 658-6100
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 8.01. Other Events.
    CPEX Pharmaceuticals, Inc. announced today that based on a full review of the results of its recently completed Phase 2a trial of Nasulin, CPEX has decided not to proceed with any further Nasulin development activities and will seek to sell or out-license the program. CPEX plans to continue identifying opportunities to out-license its CPE-215 technology and to continue building its pipeline by developing, acquiring or in-licensing new compounds.

2


 

SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  CPEX PHARMACEUTICALS, INC.
Registrant
 
 
Dated: April 12, 2010  By:   /s/ Robert P. Hebert    
    Robert P. Hebert   
    Vice President and Chief Financial Officer   
 

3